TUESDAY, April 15, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Opdivo (nivolumab) plus Yervoy ...

During a live event, Matthew Galsky, MD, discussed adjuvant nivolumab in muscle-invasive bladder cancer and the benefit in ...

Nivolumab plus ipilimumab showed a strong median overall survival (OS) advantage at 12 months and a trend toward overall ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

In the trial, researchers are evaluating Scancell's DNA cancer vaccines SCIB1 and iSCIB1+ alongside immunotherapy.

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.